New antibody drug takes aim at Hard-to-Treat cancers
NCT ID NCT07046923
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 36 times
Summary
This early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and get an early look at whether the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute Hospital of JFCR
RECRUITINGTokyo, 135-8550, Japan
-
Centre Leon Berard
RECRUITINGLyon, 69373, France
-
Columbia University
RECRUITINGNew York, New York, 10032, United States
-
Community Health Network
NOT_YET_RECRUITINGIndianapolis, Indiana, 46250, United States
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute
RECRUITINGOrlando, Florida, 32827, United States
-
Florida Cancer Specialists - Sarasota
RECRUITINGSarasota, Florida, 34236, United States
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
John Theurer Cancer Center At Hackensack UMC
RECRUITINGHackensack, New Jersey, 07601, United States
-
Kyoto University Hospital
RECRUITINGKyoto, 606-8507, Japan
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
National Cancer Center Hospital
RECRUITINGTokyo, 104-0045, Japan
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, 03722, South Korea
-
Shanghai East Hospital, Tongji University
NOT_YET_RECRUITINGShanghai, 0200120, China
-
Stanford Medicine Cancer Center
RECRUITINGStanford, California, 94305, United States
-
The Ohio State University (OSU) Wexner Medical Center
RECRUITINGColumbus, Ohio, 43210, United States
-
The University of Chicago Medical Center (UCMC)
RECRUITINGChicago, Illinois, 60637, United States
-
Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology
NOT_YET_RECRUITINGWuhan, 430030, China
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
-
West China Hospital, Sichuan University
NOT_YET_RECRUITINGChengdu, 610041, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY4175408 (an antibody drug conjugate that targets PTK7 on tumor cells, given by IV infusion, sometimes with pembrolizumab, carboplatin, or cisplatin)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced lung, endometrial, or triple-negative breast cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial, so the drug may not be safe or effective. Side effects are unknown, and the study is small (240 people) with no guarantee of benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.